Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease (Q37702722)

22 August 2017

1 reference

title

Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease (English)

1 reference

22 August 2017

1 reference

Peter A McCullough

1

1 reference

22 August 2017

Thomas A Verrill

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

22 August 2017

published in

Postgraduate Medicine

1 reference

22 August 2017

volume

122

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

25-34

1 reference

Sudden cardiac death and dialysis patients

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Chronic kidney disease and sudden death: strategies for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Cardiovascular disease in chronic kidney disease from a cardiologist's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Angiotensin II subtype 1 receptor blockers and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Role for $beta;-blockers in the management of diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Rationale for double renin-angiotensin-aldosterone system blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Managing dyslipidemia in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

The metabolic syndrome and chronic kidney disease in U.S. adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Statins and progressive renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Effect of pravastatin on cardiovascular events in people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Effect of pravastatin in people with diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Pravastatin and cardiovascular risk in moderate chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Statins for improving renal outcomes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Effect of lipid reduction on the progression of renal disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Statin-fibrate combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Review article: Risks of coronary artery calcification in chronic kidney disease: do the same rules apply?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

The renal risks of smoking: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Helping smokers with cardiac disease to abstain from tobacco after a stay in hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

The impact of advanced chronic kidney disease on in-hospital mortality following percutaneous coronary intervention for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Impact of optimal medical therapy and revascularization on outcome of patients with chronic kidney disease and on dialysis who presented with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Impact of renal dysfunction on 1-year mortality after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Pharmacotherapy for heart failure in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Acute coronary syndromes in patients with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Outcomes after percutaneous coronary interventions in patients with CKD: improved outcome in the stenting era.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Mortality of patients with renal dysfunction after percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2119

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.03.2119

1 reference

release_fwyo6hizyjep5bv6kqepipdm3y

22 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fwyo6hizyjep5bv6kqepipdm3y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference